Bone Health Technologies Closes $2.5 Million Funding Round and Appoints New Board Members
03 Maio 2021 - 11:00AM
Bone Health Technologies, a leading innovator of
technologies for improving bone health, announces today the close
of its
$2.5 million funding round and the
appointment of three board members:
Karen Drexler, MBA,
Nancy Lynch, MD, MBA and
Sam Goldberger, MD,
MBA.
“Our mission is to provide an effective and safe
treatment for the more than 40 million Americans with low bone
density - this capital and the expertise we are bringing to bear is
exactly what we need to complete our pivotal trial and bring this
important innovation to market,” shared Laura Yecies, CEO of Bone
Health Technologies (BHT).
“We have been involved with Bone Health
Technologies since the early proof of concept stage and are
thrilled to lead this investment round - the unmet need and hence
the business opportunity is enormous” said John Osborne, Managing
Partner, Good Growth Capital. Good Growth Capital led the
oversubscribed funding round which includes investments by Astia
Angels, Ambit Health Ventures, Portfolia Femtech Fund, IT-Farm,
Golden Seeds, Berkeley Angel Network, the Band of Angels, Reno Seed
Fund as well as prominent individual Angel Investors.
A founding member of Astia Angels, Karen Drexler
now joins the Bone Health Technologies board in addition to her
board positions at ResMed (RSMD:NYSE), Outset Medical (Nasdaq:OM),
Tivic Health and VIDA Diagnostics. She brings extensive commercial
and technical experience to the board team from a variety of health
and medical focused organizations.
Sam Goldberger, MD, MBA brings significant medical
expertise to the BHT board. Dr. Goldberger is Co-Founder and
Managing Partner of Ambit Health Ventures and has over 28 years of
surgical experience. Nancy Lynch, MD, MBA is also joining the
board. Dr. Lynch has more than 25 years of experience in the
clinical and business elements of orthopedics. She is a
Board-certified, fellowship-trained orthopedic surgeon and a fellow
of the American Academy of Orthopedic Surgeons and has served as
Chief Medical Officer of and consultant to several medical device
companies.
The round and board appointments add to a
successful year for BHT. It recently appointed CEO Laura Yecies and
was granted Breakthrough Device Designation by the FDA for
OsteoBoost, the first vibration belt specifically designed for the
prevention of osteoporosis. At the 2021 One Harvard New Venture
Competition, Bone Health Technologies was awarded both the One
Harvard New Venture Competition Grand Prize Winner and Northern
California Crowd Favorite titles.
Osteoboost is based on NASA research which proved
that medical stimulation of bones through vibration would improve
bone health in astronauts. Studies have shown that one 30-minute
treatment with OsteoBoost reduced bone loss activity in all study
participants.
For more information on the CEO appointment or Bone
Health Technologies and OsteoBoost please visit:
http://www.bonehealthtech.com/
ABOUT BONE HEALTH
TECHNOLOGIES:Bone Health Technologies is a San Francisco
based company that applies science and medical expertise to create
better health outcomes for women and men at risk of developing
osteoporosis and the associated bone fractures. Initially created
in the med-tech incubator TheraNova, Bone Health Technologies is
poised to become the new standard of care in treating both
osteoporosis and osteopenia (the precursor to osteoporosis). Visit
www.bonehealthtech.com for more information.
MEDIA CONTACT:
Michelle Kafka
407-603-5716
Michelle@kafkamediagroup.com
ResMed (NYSE:RMD)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
ResMed (NYSE:RMD)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024